Pulmonary - Allergy Drugs Advisory Committee
Meeting on February 23, 2012, from 8:30 a.m. to 5 p.m.
Agenda: The committee will discuss new drug application 202450, for aclidinium bromide, sponsored by Forest Laboratories, for the proposed indication of long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment